Decreased Double Product at Rest in Patients With Severe Vasospasm

Saito, Yuichi; Kitahara, Hideki; Shoji, Toshihiro; Nakayama, Takashi; Fujimoto, Yoshihide; Kobayashi, Yoshio

doi:10.1016/j.hlc.2020.02.007

Cited by 3 publications

(2 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Intracoronary ACh provocation tests were performed to diagnose VSA based on the guidelines [16,17], as previously reported [4,[18][19][20][21][22][23]. In brief, all vasodilators including calcium channel blockers and long-acting nitrates were discontinued at least 48 h before the examination in elective cases, except for sublingual nitroglycerin as needed.…”

Section: Intracoronary Acetylcholine Provocation Testsmentioning

confidence: 99%

“…Vasospastic angina (VSA) is an important cardiac disorder that is associated with the deterioration of quality of life and can induce myocardial infarction and sudden cardiac death [1]. Endothelial dysfunction with deficiency of nitric oxide plays a key role in the mechanism of VSA [2], as well as inflammation, autonomic nerve system, and rho-kinase activity [3,4].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Relation Between Cancer and Vasospastic Angina

Matsumoto

Saito

et al. 2021

Adv Ther

Self Cite

View full text Add to dashboard Cite

Introduction: Patients with cancer have an increased risk of cardiovascular disease including ischemic heart disease and vice versa. Anticancer drugs and radiotherapy are known to contribute to endothelial injury and vasospasm. However, the relations between vasospastic angina (VSA) and cancer or its treatment are poorly investigated. Methods: A total of 786 patients underwent intracoronary acetylcholine (ACh) provocation tests to diagnose VSA. The positive ACh provocation test was defined as angiographic coronary artery spasm accompanied by chest pain and/or ischemic electrocardiographic changes. Patients were divided into active cancer, a history of cancer, and no cancer according to the status of malignancy. The impact of types of cancer, anticancer drugs, and radiotherapy on VSA was evaluated. Results: Of 786 patients, 38 (4.8%) and 84 (10.7%) had active cancer and a history of cancer, respectively, and 401 (51.0%) were diagnosed as VSA. There was no significant difference in rates of positive ACh test among patients with active cancer, a history of cancer, and no cancer (39.5% vs. 57.1% vs. 50.9%, p = 0.20). Types of cancer and cancer treatment also had no impact on positive ACh provocation test. Conclusions: In this cross-sectional observational study, we did not find an association of active and a history of cancer with the diagnosis of VSA. Anticancer treatment including chemotherapy and radiotherapy was not significantly associated with positive ACh provocation test.

show abstract